| Berry, James M |
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol |
|
|
| Available | 2/3 | 40 | US | RAPA-501 Autologous T cells | Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS) | Amyotrophic Lateral Sclerosis | | | | |
| Recruiting | 2/3 | 41 | US | RAPA-501 Autologous T cells, RAPA-501 cells | Rapa Therapeutics LLC, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/26 | 06/27 | | |
| Active, not recruiting | 2a | 12 | US | Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Individualized therapy Treg cell infusions + Interleukin-2 (IL-2), Proleukin is brand name for IL-2, Monthly placebo infusions + 3 times per week placebo injections, inactive drug, Proleukin is the brand name for IL-2 | The Methodist Hospital Research Institute, Massachusetts General Hospital, The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston, North East Amyotrophic Lateral Sclerosis Consortium | ALS (Amyotrophic Lateral Sclerosis) | 05/22 | 08/22 | | |
EPISOD1, NCT06100276: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) |
|
|
| Recruiting | 1/2 | 20 | US | AMT-162 | UniQure Biopharma B.V. | Amyotrophic Lateral Sclerosis | 09/26 | 03/31 | | |
NCT04081714: Intermediate Expanded Access Protocol CNMAu8.EAP03 |
|
|
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine, University of Texas, Southwestern Medical Center at Dallas | Multiple Sclerosis | | | | |
| No Longer Available | N/A | | US | Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL | Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis | | | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Active, not recruiting | N/A | 300 | Canada, US | Edaravone (Radicava®/Radicava ORS®), Radicava®, Radicava ORS® | Mitsubishi Tanabe Pharma America Inc., Massachusetts General Hospital | Amyotrophic Lateral Sclerosis, ALS | 03/24 | 03/24 | | |
TALS LB, NCT05137665: Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures |
|
|
| Recruiting | N/A | 1000 | US, RoW | | Target ALS Foundation, Inc. | Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease | 12/31 | 12/31 | | |
NCT05976672: Machine Learning Technology in Predicting Relapse and Implementing Peer Recovery Intervention Before Drug Use Occurs |
|
|
| Recruiting | N/A | 500 | US | PRSS (Peer Recovery Support Specialist) | West Virginia University | Substance Abuse Disorder | 04/28 | 04/28 | | |
| Swenson, Andrea |
| Terminated | 3 | 489 | Europe, Canada, US, RoW | Reldesemtiv, Placebo | Cytokinetics | Amyotrophic Lateral Sclerosis | 07/23 | 07/23 | | |
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol |
|
|
| Available | 2/3 | 40 | US | RAPA-501 Autologous T cells | Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS) | Amyotrophic Lateral Sclerosis | | | | |
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04 |
|
|
| Available | N/A | | US | CNM-Au8 | Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS) | ALS, Amyotrophic Lateral Sclerosis, PALS | | | | |
| No Longer Available | N/A | | US | Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL | Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis | | | | |
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) |
|
|
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles | Myotonic Dystrophy 1, DM1 | 10/26 | 12/26 | | |
| Morgan, Todd M |
| Recruiting | 3 | 870 | US | Gemcitabine, GEMZAR, Docetaxel, Taxotere, Bacillus Calmette Guerin, BCG | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Non-muscle-invasive Bladder Cancer | 11/29 | 10/30 | | |
GUNS, NCT04812366: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer |
|
|
| Recruiting | 2 | 315 | Canada, US | Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab | University of British Columbia, Janssen Inc., University Health Network, Toronto | Prostate Cancer | 04/26 | 04/26 | | |
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects |
|
|
| Active, not recruiting | 2 | 70 | US | Olaparib, Lynparza, Abiraterone Acetate, Prednisone | Northwestern University, AstraZeneca, National Cancer Institute (NCI) | Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer | 12/26 | 01/27 | | |
| Completed | N/A | 356 | US | Decipher Prostate Cancer Classifier, Decipher Post-Op | University of Michigan Rogel Cancer Center, Michigan Urological Surgery Improvement Collaborative (MUSIC), GenomeDx Biosciences Corp | Prostate Cancer | 02/20 | 04/24 | | |
NCT04396808: Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer |
|
|
| Recruiting | N/A | 900 | US | Decipher, Decipher Prostate Cancer Classifier, Prolaris, Prolaris Prostate Cancer Test, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score), askMUSIC score | University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), Myrexis Inc., Veracyte, Inc., MDx Health | Prostate Cancer | 07/25 | 07/25 | | |
| Recruiting | N/A | 3000 | Canada, US | | University of Washington, Canary Foundation, Early Detection Research Network | Prostatic Neoplasms | 09/29 | 09/32 | | |
| Recruiting | N/A | 10000 | Europe, US | | Target PharmaSolutions, Inc. | Hepatocellular Cancer | 10/25 | 10/25 | | |
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection |
|
|
| Recruiting | N/A | 5000 | Canada, US | All approved therapies for the treatment of Chronic Hepatitis B (CHB) | Target PharmaSolutions, Inc. | Hepatitis B, Hepatitis, Liver Diseases | 01/26 | 01/26 | | |
| Heitzman, Daragh |
| Terminated | 3 | 489 | Europe, Canada, US, RoW | Reldesemtiv, Placebo | Cytokinetics | Amyotrophic Lateral Sclerosis | 07/23 | 07/23 | | |
| Terminated | 3 | 71 | Europe, Canada, US, RoW | Reldesemtiv | Cytokinetics, Cytokinetics Inc | Amyotrophic Lateral Sclerosis | 06/23 | 06/23 | | |
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 270 | US, RoW | Ulviprubart (ABC008) | Abcuro, Inc. | Inclusion Body Myositis (IBM) | 01/29 | 04/29 | | |
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 231 | Europe, Canada, US, RoW | ABC008 | Abcuro, Inc., Syneos Health | Inclusion Body Myositis | 11/25 | 12/25 | | |
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04 |
|
|
| Available | N/A | | US | CNM-Au8 | Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS) | ALS, Amyotrophic Lateral Sclerosis, PALS | | | | |
| No Longer Available | N/A | | US | Trehalose, SLS-005 Intravenous Trehalose Injection 90.5 mg/mL | Seelos Therapeutics, Inc., Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis | | | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Arcila-Londono, Ximena |
| Terminated | 3 | 489 | Europe, Canada, US, RoW | Reldesemtiv, Placebo | Cytokinetics | Amyotrophic Lateral Sclerosis | 07/23 | 07/23 | | |
| Terminated | 3 | 71 | Europe, Canada, US, RoW | Reldesemtiv | Cytokinetics, Cytokinetics Inc | Amyotrophic Lateral Sclerosis | 06/23 | 06/23 | | |
| Not yet recruiting | 1 | 8 | US | XT-150 | Xalud Therapeutics, Inc. | Amyotrophic Lateral Sclerosis (ALS) | 06/26 | 06/26 | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Wagoner, Mary |
| Recruiting | 2/3 | 230 | Canada, US | MN-166, ibudilast, placebo | MediciNova | Amyotrophic Lateral Sclerosis | 12/25 | 12/26 | | |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
| Neate, Crystal |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
| Duthie, Beverley |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Ward, Michelle |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
NCT06429059: ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments |
|
|
| Active, not recruiting | 2 | 50 | US | Astaxanthin, Protandim, Melatonin, MitoQ | Duke University, Temple University | Amyotrophic Lateral Sclerosis ALS | 05/25 | 05/25 | | |
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04 |
|
|
| Available | N/A | | US | CNM-Au8 | Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS) | ALS, Amyotrophic Lateral Sclerosis, PALS | | | | |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Carlson, Danielle |
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 270 | US, RoW | Ulviprubart (ABC008) | Abcuro, Inc. | Inclusion Body Myositis (IBM) | 01/29 | 04/29 | | |
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 231 | Europe, Canada, US, RoW | ABC008 | Abcuro, Inc., Syneos Health | Inclusion Body Myositis | 11/25 | 12/25 | | |
NCT05738096: Trigeminal Evoked Responses to Improve Rhizotomy |
|
|
| Recruiting | 1 | 30 | US | TSEP + rhizotomy surgery, TSEPs recording only | University of Minnesota | Trigeminal Neuralgia, Rhizotomy | 11/26 | 11/26 | | |
| Recruiting | N/A | 30 | US | Trigeminal Electrophysiology | University of Minnesota | Trigeminal Neuralgia | 04/25 | 04/25 | | |
| Nasri, Mohamad |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
NCT06408727: Intermediate Expanded Access Protocol CNMAu8.EAP04 |
|
|
| Available | N/A | | US | CNM-Au8 | Clene Nanomedicine, National Institute of Neurological Disorders and Stroke (NINDS) | ALS, Amyotrophic Lateral Sclerosis, PALS | | | | |
| Nagaraj, Arun |
| Recruiting | 3 | 800 | Europe, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
NCT05671055: CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis |
|
|
| Completed | N/A | 300 | Europe, US | Custom study version of icompanion app | icometrix, Bristol-Myers Squibb | Multiple Sclerosis | 12/23 | 12/23 | | |
| Heitzman |
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 231 | Europe, Canada, US, RoW | ABC008 | Abcuro, Inc., Syneos Health | Inclusion Body Myositis | 11/25 | 12/25 | | |
| Halawani, Hanan Al |
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 270 | US, RoW | Ulviprubart (ABC008) | Abcuro, Inc. | Inclusion Body Myositis (IBM) | 01/29 | 04/29 | | |
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 231 | Europe, Canada, US, RoW | ABC008 | Abcuro, Inc., Syneos Health | Inclusion Body Myositis | 11/25 | 12/25 | | |
| Coriddi, Angela |
| Available | N/A | | US | CNM-Au8, Nanocrystalline gold | Clene Nanomedicine | Amyotrophic Lateral Sclerosis | | | | |
| Kent-Baron, Randee |
| Active, not recruiting | 2/3 | 1500 | US | ABBV-CLS-7262, DNL343 | Merit E. Cudkowicz, MD, Massachusetts General Hospital | Amyotrophic Lateral Sclerosis | 07/25 | 04/26 | | |
| Recruiting | N/A | 1200 | US | | University of Miami, Muscular Dystrophy Association, National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy | 06/25 | 06/25 | | |
| Aburashed, Rany |
| Recruiting | 3 | 800 | Europe, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD |
|
|
| Completed | 2/3 | 320 | US | Buntanetap/Posiphen, Posiphen Tartrate, Placebo | Annovis Bio Inc. | Alzheimer Disease | 02/24 | 02/24 | | |
| Hua, Vivian |
NCT06450886: Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 270 | US, RoW | Ulviprubart (ABC008) | Abcuro, Inc. | Inclusion Body Myositis (IBM) | 01/29 | 04/29 | | |
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 231 | Europe, Canada, US, RoW | ABC008 | Abcuro, Inc., Syneos Health | Inclusion Body Myositis | 11/25 | 12/25 | | |
| Naddaf, Elie |
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis |
|
|
| Active, not recruiting | 2/3 | 231 | Europe, Canada, US, RoW | ABC008 | Abcuro, Inc., Syneos Health | Inclusion Body Myositis | 11/25 | 12/25 | | |
| Arroyo, Victor Bolivar |
| Recruiting | 3 | 800 | Europe, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
NCT06167343: Comparison of Semitendinosus and Quadriceps Grafts for Anterior Cruciate Ligament Reconstruction |
|
|
| Active, not recruiting | N/A | 54 | Europe | ACL reconstruction | Universidad de Granada, Hospital Vithas | ACL, ACL Injury | 09/25 | 12/25 | | |
SPINNERS, NCT05458908: ProSPective Evaluation of Non-contrast sINe spiN Flat-dEtectoR CT for the Detection of Intracranial hemorrhageS |
|
|
| Recruiting | N/A | 252 | Europe, US | Non-contrast cranial MDCT head scan, Non-contrast syngo DynaCT Sine Spin head scan and application software | University Hospital, Basel, Switzerland, Siemens Healthineers AG | Stroke | 04/25 | 07/25 | | |
| Ngwueke, Agatha |
| Recruiting | 3 | 800 | Europe, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
| Recruiting | 2 | 48 | US | Artesunate ointment, Artesunic acid, Dihydroartemisinin (DHA), Artemisinin, Placebo, placebo ointment | Frantz Viral Therapeutics, LLC, Laser Surgery Care, LLC, Anal Dysplasia Clinic MidWest | Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection | 12/25 | 12/25 | | |
| Rucker, Haley |
MAGIC, NCT06282159: A Phase 2 Study to Evaluate DNTH103 in Adults with Generalized Myasthenia Gravis |
|
|
| Recruiting | 2 | 60 | Europe, Canada, US, RoW | DNTH103, Placebo | Dianthus Therapeutics | Myasthenia Gravis, Generalized | 12/25 | 12/27 | | |
| Recruiting | N/A | 600 | US | | St. Joseph's Hospital and Medical Center, Phoenix, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Foundation for the National Institutes of Health | Amyotrophic Lateral Sclerosis | 01/29 | 07/29 | | |
| Recruiting | N/A | 2000 | US | | St. Joseph's Hospital and Medical Center, Phoenix, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Foundation for the National Institutes of Health | Amyotrophic Lateral Sclerosis | 01/29 | 07/29 | | |
| Rice, Danielle |
| Recruiting | 3 | 800 | Europe, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
| Poulos, Cati |
NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2) |
|
|
| No Longer Available | N/A | | US | Pridopidine | Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis | | | | |
| Failor, Carly |
| Recruiting | N/A | 600 | US | | St. Joseph's Hospital and Medical Center, Phoenix, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Foundation for the National Institutes of Health | Amyotrophic Lateral Sclerosis | 01/29 | 07/29 | | |
| Recruiting | N/A | 2000 | US | | St. Joseph's Hospital and Medical Center, Phoenix, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Foundation for the National Institutes of Health | Amyotrophic Lateral Sclerosis | 01/29 | 07/29 | | |
| Hare, Michele |
| Recruiting | N/A | 600 | US | | St. Joseph's Hospital and Medical Center, Phoenix, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Foundation for the National Institutes of Health | Amyotrophic Lateral Sclerosis | 01/29 | 07/29 | | |
| Recruiting | N/A | 2000 | US | | St. Joseph's Hospital and Medical Center, Phoenix, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), Foundation for the National Institutes of Health | Amyotrophic Lateral Sclerosis | 01/29 | 07/29 | | |
| Pinal, Amanda |
NCT06069934: Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2) |
|
|
| No Longer Available | N/A | | US | Pridopidine | Prilenia, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) | Amyotrophic Lateral Sclerosis | | | | |
